Price (delayed)
$27.45
Market cap
$924.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.65
Enterprise value
$642.35M
We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize
There are no recent dividends present for AVBP.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.